Added to YB: 2026-09-03
Pitch date: 2026-09-01
NWBO [bullish]
Northwest Biotherapeutics, Inc.
Author Info
No bio for this author
Company Info
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer.
Market Cap
$290.3M
Pitch Price
$0.17
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.78
P/E
-6.85
EV/Sales
164.06
Sector
Biotechnology
Category
special_situation
When Will NWBO Be Loved?
NWBO: Northwest Biotherapeutics’ ~$300M valuation could change materially if the MHRA approves DCVax-L, which has produced statistically significant Phase 3 results and has had a U.K. application pending for nearly 1,000 days. Approval before year-end 2026 could enable more than $100M of 2027 revenue, NICE reimbursement, international filings and franchise partnerships. The central risk is continued regulatory delay, compounded by limited capital and management depth.
Read full article (4 min)